Talis Biomedical Corporat... (TLIS)
OTC: TLIS
· Real-Time Price · USD
1.06
-0.54 (-33.75%)
At close: Apr 04, 2025, 9:37 AM
Talis Biomedical Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 73K | 151K | 76K | 48K | 137K | 107K | 730K | 502K | 2.31M | -218 | 218.00 | n/a | n/a |
Cost of Revenue | 84K | 268K | 622K | 6K | 7K | 20K | 2.33M | 1.24M | 1.3M | 3.52M | 967K | 716K | 579K | n/a |
Gross Profit | -84K | -195K | -471K | 70K | 41K | 117K | -2.23M | -506K | -800K | -1.21M | -967.22K | -715.78K | -579K | n/a |
Operating Income | -9.58M | -9.15M | -14.5M | -16.97M | -16.39M | -19M | -28.11M | -26.79M | -27.27M | -32.97M | -28.52M | -38.41M | -64.36M | -60.52M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -8.85M | -13.04M | -13.46M | -15.68M | -15.03M | -17.83M | -26.93M | -26.02M | -27.01M | -33.05M | -28.65M | -38.42M | -64.47M | -60.49M |
Net Income | -8.85M | -13.04M | -13.46M | -15.68M | -15.03M | -16.66M | -26.93M | -25.26M | -26.75M | -33.13M | -28.65M | -38.42M | -64.47M | -60.49M |
Selling & General & Admin | 7.98M | 6.42M | 5.99M | 8.8M | 6.41M | 6.4M | 10.8M | 8.82M | 9.18M | 11.93M | 12.32M | 12.79M | 9.98M | 7.33M |
Research & Development | 1.6M | 2.53M | 8.04M | 8.3M | 10.55M | 13.8M | 15.24M | 17.52M | 17.36M | 20.7M | 17.06M | 25.84M | 54.49M | 60.19M |
Other Expenses | n/a | 1.08M | 996K | 1.29M | 1.36M | -1.08M | -150K | -66K | -70K | -874K | -134K | -3K | -111K | 28K |
Operating Expenses | 9.58M | 8.95M | 14.03M | 17.04M | 16.43M | 19.11M | 25.89M | 26.28M | 26.47M | 31.76M | 28.52M | 38.41M | 64.36M | 60.52M |
Interest Expense | n/a | n/a | 1.17M | n/a | n/a | n/a | n/a | n/a | n/a | 84K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 8.58M | 9.22M | 14.65M | 17.05M | 16.44M | 19.13M | 28.22M | 27.52M | 27.77M | 35.28M | 28.52M | 38.41M | 64.36M | 60.52M |
Income Tax Expense | n/a | 218.72K | 1.17M | 256.59K | 45.91K | -1.17M | n/a | -765K | -262K | 84K | -937K | -485K | -385K | -216K |
Shares Outstanding (Basic) | 1.82M | 1.82M | 1.82M | 1.82M | 1.82M | 1.79M | 1.79M | 1.78M | 1.77M | 1.76M | 1.76M | 1.72M | 1.71M | 874.05K |
Shares Outstanding (Diluted) | 1.82M | 1.82M | 1.82M | 1.82M | 1.82M | 1.79M | 1.79M | 1.8M | 1.8M | 1.76M | 1.76M | 1.72M | 1.71M | 874.05K |
EPS (Basic) | -4.86 | -7.15 | -7.4 | -8.62 | -8.27 | -9.32 | -15.07 | -14.22 | -15.07 | -18.78 | -16.28 | -22.35 | -37.71 | -69.21 |
EPS (Diluted) | -4.86 | -7.15 | -7.4 | -8.62 | -8.27 | -9.32 | -15.07 | -14.02 | -14.86 | -18.78 | -16.28 | -22.35 | -37.71 | -69.21 |
EBITDA | -9.49M | -13.86M | -14.29M | -16.38M | -16.22M | -18.82M | -24.55M | -22.86M | -26.29M | -32.6M | -27.58M | -38.18M | -64.17M | -60.52M |
EBIT | -9.58M | -14.12M | -14.46M | -16.97M | -16.39M | -19M | -28.11M | -26.79M | -27.27M | -32.97M | -28.52M | -38.41M | -64.36M | -60.52M |
Depreciation & Amortization | 84K | 262K | 211K | 658K | 2.84M | 959K | 3.56M | 4.87M | 1.58M | 772K | 967K | 716K | 579K | 359K |